“A global alliance to protect the world’s people from toxic lead, chromium, mercury, pesticides and other pollution has been formed by the World Bank, Asian Development Bank, U.N. agencies, donor countries, foundations and non-government experts in July,” freelance journalist Ben Barber reports in this post in Huffington Post’s “Green” blog. “The Global Alliance for Health and Pollution (GAHP) aims to work together to protect the health of over one hundred million people in poor countries who are at risk from toxic pollution,” Barber writes, adding, “The group will work with governments to clean-up toxic hotspots where children, especially, are being poisoned. It could also respond to emergencies such as a recent lead poisoning outbreak in Nigeria that killed hundreds of children” (8/10).
Private Sector Involvement
U.N. Secretary-General Ban Ki-moon on Tuesday “announced the members of a High-level Panel to advise on the global development agenda beyond 2015, the target date for achieving the anti-poverty targets known as the Millennium Development Goals (MDGs),” the U.N. News Centre reports. “The eight MDGs, agreed on by world leaders at a U.N. summit in 2000, set specific targets on poverty alleviation, education, gender equality, child and maternal health, environmental stability, HIV/AIDS reduction, and a ‘Global Partnership for Development,’” the news service writes (7/31).
The XIX International AIDS Conference (AIDS 2012) that took place last week in Washington, D.C., “ignited momentum to shift from ‘fighting AIDS’ to ‘ending AIDS,’” Mohga Kamal-Yanni, senior health adviser at Oxfam International, and Urvarshi Rajcoomer, policy and advocacy adviser at Oxfam in South Africa, write in a Mail & Guardian opinion piece. “Oxfam believes investing in health systems such as infrastructure and health worker, drug supply chain and health information systems, is a critical prerequisite to ending AIDS,” they write. However, “to make this a reality,” pharmaceutical companies, donor governments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Bank “must now do their part,” they continue.
“When you’re dealing with a global public health crisis, having an international presence isn’t just advisable — it is imperative,” Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI), writes in this post in USAID’s “Impact” blog, adding, “That’s why [IAVI], in partnership with USAID, has worked diligently over the past several years to establish itself as a truly global non-profit partner.” She continues, “IAVI has created an enviable network of research centers in sub-Saharan Africa dedicated to assessing novel AIDS vaccine candidates in clinical trials and conducting supporting epidemiological studies on HIV,” and writes that these “partnerships have made meaningful contributions to the research capacity of many developing countries — a capability that is now helping local researchers tackle other diseases” (8/13).
In an opinion piece in the Guardian’s “Comment is Free” blog, Dean Baker, co-director of the Center for Economic and Policy Research, discusses potential policies contained within the “Trans-Pacific Partnership Agreement (TPP), a pact that the United States is negotiating with Australia, Canada, Japan and eight other countries in the Pacific region.” However, “[a]t this point, it’s not really possible to discuss the merits of the TPP since the governments are keeping the proposed text a secret from the public,” he says. Noting “[a] few items that have been leaked give us some insight as to the direction of this pact,” he discusses how the “pharmaceutical industry is … likely to be a big gainer” from the TPP if the pact includes “stronger and longer patent protection and also increased use of ‘data exclusivity.’”
In a post in the Guardian’s “Sustainable Business” blog, Lisa Herman, managing director of the global health practice area at consulting firm FSG, and Mike Stamp, a senior consultant with FSG, discuss “a new guide for companies on how to participate in global action on women and children’s health” recently launched at the London Family Planning Summit. “The guide, co-authored by social impact consultants FSG and sponsored by the Innovation Working Group in support of the global Every Woman, Every Child effort, sets out concrete opportunities for companies from many different industries to contribute to improving women and children’s health,” they write.
Peace Corps, PEPFAR, Global Health Service Corps Launch Public-Private Partnership To Place Medical Professionals Overseas
The Peace Corps, PEPFAR and the Global Health Service Corps on Tuesday will announce a public-private partnership program to place U.S. health workers overseas to help address medical professional shortages, CQ HealthBeat reports (Bristol, 3/12). “The Global Health Service Partnership (GHSP) will address health professional shortages by investing in capacity and building support for existing medical and nursing education programs in less-developed countries,” a joint press release (.pdf) states, adding, “The new program is expected to begin in Tanzania, Malawi and Uganda in July 2013.”
In this “Health Affairs Blog” post, Sachin Jain, a physician and former HHS adviser, explores the use of the term “strategy” in global health, writing “the term remains variably used and ill-defined.” He “offer[s] a definition enumerated for use by for-profit firms: Strategy is the unique set of activities and operating structures that an organization puts in place to deliver value to its customers,” and offers explanation about each segment of the definition. He concludes, “Strategy requires that organizations puzzle through different sets of ‘conflicting virtues’ — funders, activities, customers — and establish a priority order among them. None of these decisions are without their challenges; deciding to clearly define and grapple with them, however, will be an important step towards greater organizational effectiveness and results” (3/12).
IRIN examines ColaLife — a pilot project set to start in Zambia in September 2012 that will ship single-dose anti-diarrhea kits (ADKs) in crates of Coca-Cola bottles in an effort to increase the coverage of oral rehydration salts (ORS) for the treatment of diarrhea in children in the developing world. “Three-quarters of [diarrhea-related] deaths could be prevented with a simple course of [ORS] combined with zinc tablets, at a cost of just $0.50 per patient,” but, “despite being heavily promoted by the World Health Organization since the 1970s, fewer than 40 percent of child diarrhea cases in developing countries are treated with ORS,” the news service writes.
Inadequate Government TB Program, Lax Drug Sale Regulations Contributing To MDR-TB Cases In India, Health Groups Say
“India’s inadequate government-run tuberculosis [TB] treatment programs and a lack of regulation of the sale of drugs that fight the disease are responsible for the [increasing] number of drug-resistant cases that are difficult to treat,” health advocacy organizations said in India last week, the Associated Press/Huffington Post reports. “India adds an estimated 99,000 cases of drug-resistant TB every year, but only a tiny fraction of those infected receive the proper” six- to nine-month antibiotic regimen, according to the AP. In India, government-run TB treatment programs only provide drugs to patients on alternate days, increasing the likelihood of missed doses, and patients increasingly are turning to private physicians who are unaware of how to treat the disease, Medecins Sans Frontieres in India and other health groups said, the news agency reports. “The Indian government had no response Friday to requests for comment on the activists’ allegations,” the AP writes (Naqvi, 3/23).